T1	Participants 312 444	ddball paradigms (with task and nontask conditions), standard (80%), target (10%), and unexpected novel stimuli (10%) were presented
T2	Participants 144 286	weeks of treatment with the adrenocorticotropin4-9 analogue ORG-2766 (40 mg/day) on brain event-related potentials (ERPs) of autistic children
